4-[2-甲基-1-(5,5,8,8-四甲基-6,7-二氢萘-2-基)丙-1-烯基]苯甲酸 | 146670-35-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 4-[2-甲基-1-(5,5,8,8-四甲基-6,7-二氢萘-2-基)丙-1-烯基]苯甲酸
• 英文名称: SR11217
• 英文别名: 4-[1-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-methyl-1-propenyl]benzoic acid；4-(2-Methyl-1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid；4-[2-methyl-1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
• CAS: 146670-35-1
• 化学式: C₂₅H₃₀O₂
• 分子量: 362.512
• InChiKey: XYIWGTYPSQVWKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氯甲酰基苯甲酸甲酯 在 氢氧化钾 、 三氯化铝 、 双(三甲基硅烷基)氨基钾 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 30.08h， 生成 4-[2-甲基-1-(5,5,8,8-四甲基-6,7-二氢萘-2-基)丙-1-烯基]苯甲酸
  参考文献：
  名称：

  Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity

  摘要：

  The natural retinoid 9-cis-retinoic acid is an activating ligand for both the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which are members of the retinoid/thyroid hormone/steroid hormone family of nuclear receptor proteins that activate gene transcription through specific response elements. The pharmacophoric groups necessary to confer RXR selectivity were established by evaluating the ability of 21 conformationally restricted retinoids to activate, the TREpal retinoic acid receptor response element for gene transcription in the presence of one of the three RAR subtypes or RXR alpha. In contrast to those retinoids selective for the RARs, these RXR-selective retinoids have one less atom in the bridge linking the hydrophobic and carboxylic acid termini of the retinoid skeleton. Therefore, a one-carbon bridge replaces the 19-methyl group and SE-double bond of S-cis-retinoic acid and is further functionalized by inclusion in an isopropylidene group, a dioxolane ring, or a cyclopropane ring for optimal RXR alpha activity and selectivity. In addition, the beta-geranylidene and 20-methyl-(11E,13E)-dienoic acid groups of g-cis-retinoic acid are replaced by a 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2 naphthalenyl ring and a 4-carboxylphenyl ring, respectively, for optimal activation and selectivity. RXR alpha; selectivity is reduced on replacement of the 4-carboxylphenyl group by a 2-carboxyl-5-thienyl group or the S-cis-retinoic acid methylpentadienoic acid terminus.

  DOI：

  10.1021/jm00017a021

文献信息

• Bridged bicyclic aromatic compounds and their use in modulating gene
  申请人：SRI International

  公开号：US05466861A1

  公开（公告）日：1995-11-14

  Bridged bicyclic aromatic compounds are provided having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as defined herein. The novel compounds are useful for modulating gene expression of retinoic acid receptors, vitamin D receptors and thyroid receptors. Pharmaceutical compositions and methods for modulating gene expression are provided as well.

  提供具有以下结构的桥接双环芳香化合物：##STR1##其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和n的定义如本文所述。这些新颖化合物可用于调节视黄酸受体、维生素D受体和甲状腺受体的基因表达。同时还提供了用于调节基因表达的药物组合物和方法。
• RXR homodimer formation
  申请人：La Jolla Cancer Research Foundation

  公开号：US05824484A1

  公开（公告）日：1998-10-20

  The invention provides a method of screening a substance for the ability to effect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing retinoid X receptors and determining the presence of homodimer formation. Also provided is a method of screening a substance for an effect on a retinoid X receptor homodimer's ability to bind DNA comprising combining the substance with the homodimer and determining the effect of the compound on the homodimer's ability to bind DNA. A method of inhibiting an activity of a retinoid X receptor heterodimer comprising increasing the formation of a retinoid X receptor homodimer, thereby preventing the retinoid X receptor from forming a heterodimer and preventing the resulting heterodimer activity is also provided. A method of inhibiting an activity of a retinoid X receptor homodimer is also provided. A method of determining an increased probability of a pathology associated with retinoid X receptor homodimer formation and treating such pathology are further provided. In addition, a method of screening a response element for binding with a retinoid X receptor homodimer is provided. Finally, the invention provides methods of activating retinoid X receptor homodimer formation.

  本发明提供了一种筛选物质对影响视黄酸X受体同源二聚体形成能力的方法，包括将该物质与含有视黄酸X受体的溶液结合，并确定同源二聚体形成的存在。还提供了一种筛选物质对视黄酸X受体同源二聚体结合DNA能力的影响的方法，包括将该物质与同源二聚体结合，并确定该化合物对同源二聚体结合DNA能力的影响。本发明还提供了一种抑制视黄酸X受体异源二聚体活性的方法，包括增加视黄酸X受体同源二聚体的形成，从而防止视黄酸X受体形成异源二聚体并防止由此产生的异源二聚体活性。本发明还提供了一种抑制视黄酸X受体同源二聚体活性的方法。此外，本发明还提供了一种确定与视黄酸X受体同源二聚体形成相关的病理概率增加并治疗此类病理的方法。此外，本发明还提供了一种筛选响应元件与视黄酸X受体同源二聚体结合的方法。最后，本发明提供了激活视黄酸X受体同源二聚体形成的方法。
• (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
  申请人：ORYZON GENOMICS, S.A.

  公开号：US20150119396A9

  公开（公告）日：2015-04-30

  The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

  本发明涉及（杂）芳基环丙胺化合物，特别是公式（I）所描述和定义的化合物，以及它们在治疗中的应用，包括但不限于治疗或预防癌症、神经系统疾病或病情，或病毒感染。
• (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
  申请人：Oryzon Genomics, S.A.

  公开号：US10329256B2

  公开（公告）日：2019-06-25

  The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

  本发明涉及(杂)芳基环丙胺化合物，尤其包括本文所描述和定义的式 I 化合物，以及它们在治疗中的用途，包括治疗或预防癌症、神经系统疾病或病症或病毒感染等。
• RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION
  申请人：LA JOLLA CANCER RESEARCH FOUNDATION

  公开号：EP0671005A1

  公开（公告）日：1995-09-13